EGFR and glioblastoma: In general, we have shown that the RevCAR system enables targeting of GBM cells effectively with improved controllability, while providing a safety switch and combinatorial targeting approach in order to prevent any therapy-related complications, and to spare healthy tissues that minimally express EGFR and GD2.